These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6883933)

  • 1. Steady-state salicylate plasma and urinary metabolite concentrations from plain, buffered, or enteric-coated aspirin.
    Allen JH; Thakker KM; Small RE; Wood JH; Willis HE
    Clin Pharm; 1983; 2(1):64-6. PubMed ID: 6883933
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
    Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum salicylate concentrations after aspirin administration at 6- or 12-hour intervals.
    Butler CD; Straughn AB
    Clin Pharm; 1982; 1(5):458-60. PubMed ID: 7184679
    [No Abstract]   [Full Text] [Related]  

  • 4. Salicylate-induced gastrointestinal bleeding: comparison between soluble buffered, enteric-coated, and intravenous administration.
    Mielants H; Verbruggen G; Schelstraete K; Veys EM
    J Rheumatol; 1979; 6(2):210-8. PubMed ID: 313448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability.
    Portek I; Graham G; Fleming A
    Med J Aust; 1981 Jul; 2(1):39-40. PubMed ID: 6974303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma salicylate levels in rheumatoid arthritis produced by four different salicylate preparations.
    Armstrong BK; Ukich AW; Goatcher PM
    Med J Aust; 1970 Jul; 2(4):181-3. PubMed ID: 4917130
    [No Abstract]   [Full Text] [Related]  

  • 7. The bioavailability of enteric-coated acetylsalicylic acid: a comparison with buffered ASA in rheumatoid arthritis II.
    Canada AT; Little AH; Creighton EL
    Curr Ther Res Clin Exp; 1976 May; 19(5):554-7. PubMed ID: 820521
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma salicylate concentrations following chronic administration of aspirin as conventional and sustained-release tablets.
    Wiseman EH
    Curr Ther Res Clin Exp; 1969 Nov; 11(11):681-9. PubMed ID: 4982303
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative bioavailability of sustained-release and uncoated aspirin tablets.
    Karahalios WJ; Sawyer WT; Rittase RA; Maynard SA
    Am J Hosp Pharm; 1981 Nov; 38(11):1754-6. PubMed ID: 7304632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum salicylate concentrations and endoscopic evaluation of the gastric mucosa in dogs after oral administration of aspirin-containing products.
    Lipowitz AJ; Boulay JP; Klausner JS
    Am J Vet Res; 1986 Jul; 47(7):1586-9. PubMed ID: 3740630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Enteric aspirin tablets and the salicylate concentration in the plasma in the morning].
    Laine V; Strandman D; Tikkanen R
    Lakartidningen; 1968 Sep; 65(39):3832-7 passim. PubMed ID: 5741894
    [No Abstract]   [Full Text] [Related]  

  • 12. [Analgesics; the use of aspirin in dogs; effects of tablet type and food intake on plasma salicylate level].
    Nap RC; Breen DJ; Lam TJ; Peters IO; Willemsen A; De Bruyne JJ
    Tijdschr Diergeneeskd; 1993 Jul; 118(13):439-42. PubMed ID: 8346511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cimetidine on bioavailability of enteric-coated aspirin tablets.
    Paton TW; Walker SE; Leung FY; Little AH
    Clin Pharm; 1983; 2(2):165-6. PubMed ID: 6883946
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations.
    Schwertner HA; McGlasson D; Christopher M; Bush AC
    Thromb Res; 2006; 118(4):529-34. PubMed ID: 16298420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vivo drug release from microencapsulated acetylsalicylic acid with simultaneous alcohol uptake].
    Frömming KH; Schwabe L
    Arzneimittelforschung; 1980; 30(5):836-9. PubMed ID: 7190431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
    Petroski D
    Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an enteric coated aspirin preparation.
    Day RO; Paull PD; Champion GD; Graham GG
    Aust N Z J Med; 1976 Feb; 6(1):45-50. PubMed ID: 1065299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of salicylate during chronic aspirin therapy.
    Rumble RH; Brooks PM; Roberts MS
    Br J Clin Pharmacol; 1980 Jan; 9(1):41-5. PubMed ID: 7356892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of enteric coating of aspirin tablets on occult gastrointestinal blood loss.
    Howe GB; Champion GD; Corrigan AB; Hewson J; Haski A; Day RO; Paull PD; Graham GG
    Aust N Z J Med; 1977 Dec; 7(6):600-4. PubMed ID: 350214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.